KVUE

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Monday, December 4, 2023
Nasal, Food, Risk, Johnson & Johnson, CFR, Phenylephrine, Petition, J&J, LLP, FDA, Ext, Court, Initiative, Find, Person, Nasal congestion, Register, News, Complaint, Pomerantz, KVUE, Prior, Prospectus, Safety, Defendant, District court, Action Replay, Pharmaceutical industry

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

KENVUE SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kenvue To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, December 2, 2023
Risk, Johnson & Johnson, Phenylephrine, LLP, FDA, Court, Complaint, KVUE, Advertising, Prospectus, Defendant, Woman, Security (finance)

NEW YORK, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and reminds investors of the December 8, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Kenvue’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

KVUE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE

Retrieved on: 
Saturday, December 2, 2023
Titan, Phenylephrine, Court, Register, KVUE, Advertising, Prospectus, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kenvue, Inc. (KVUE) Investors with Substantial Losses to Contact its Attorneys Before Dec. 8th Deadline in Securities Fraud Class Action

Retrieved on: 
Friday, December 1, 2023
Risk, Phenylephrine, FDA, Hagens Berman, SAN, KVUE, Person, IPO, Pharmaceutical industry

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

KENVUE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kenvue Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 1, 2023
Telephone, Risk, Phenylephrine, Person, Court, Register, P.C, KVUE, IPO, Prospectus, District court

Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • If you purchased or otherwise acquired Kenvue shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Thursday, November 30, 2023
Suite, Nasal, Risk, Johnson & Johnson, Phenylephrine, FDA, GPM, Court, Nasal congestion, Register, News, KVUE, Prospectus, Defendant, Security (finance)

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kenvue Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 8, 2023 – (NYSE: KVUE)

Retrieved on: 
Thursday, November 30, 2023
NEXT, Prospectus, Fraud, Person, Risk, CLASS, Phenylephrine, KVUE, Security (finance)

DEADLINE: December 8, 2023 Shareholders should not delay in registering for this class action.

Key Points: 
  • DEADLINE: December 8, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is December 8, 2023.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Kenvue Inc. (KVUE) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Wednesday, November 29, 2023
Telephone, NEXT, Risk, Phenylephrine, LLP, Person, Court, CLASS, COST, KVUE, Prospectus

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kenvue Inc. ("Kenvue" or the "Company") (NYSE: KVUE) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kenvue Inc. ("Kenvue" or the "Company") (NYSE: KVUE) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kenvue investors who were adversely affected by alleged securities fraud.
  • Follow the link below to get more information and be contacted by a member of our team:
    KVUE investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

KENVUE INC. (NYSE: KVUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Kenvue Inc.

Retrieved on: 
Tuesday, November 28, 2023
Food, Phenylephrine, Court, Register, Disclosure, Complaint, KVUE, Advertising, IPO, Prospectus, District court, Security (finance)

If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.

Key Points: 
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Final Deadline Approaching for Kenvue Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Kenvue Inc. (KVUE) Investors of December 8, 2023 Lead Plaintiff Deadline

Retrieved on: 
Tuesday, November 28, 2023
Lead, Johnson & Johnson, LLP, Court, News, COPY, Insurance, KVUE, IPO, District court

As a result of Kenvue’s materially misleading statements and omissions to the public, Kenvue’s investors have suffered significant losses.

Key Points: 
  • As a result of Kenvue’s materially misleading statements and omissions to the public, Kenvue’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Kenvue investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.